We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 149.92 | 0 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit and Legend Biotech Corp. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of their cell-based therapy Carvykti for certain patients with the blood cancer multiple myeloma.
The companies said the recommendation covers Carvykti for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and have shown disease progression on the last therapy.
Janssen and Legend, a Somerset, N.J.-based biotechnology company, in late 2017 struck an exclusive world-wide license and collaboration agreement to develop and commercialize Carvykti.
The U.S. Food and Drug Administration last month approved Carvykti, making it the first customized, cell-based treatment in the U.S. to be developed initially in China.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 25, 2022 08:34 ET (12:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
